According to a new report issued by London-based Datamonitor, sales forces are growing in size, but sales force return on investment is decreasing. The report reveals that physicians have less time to see sales representatives but are contacted by an increasing number as pharmaceutical sales forces expand. Therefore, reps are spending an increasing proportion of their time trying to gain access to physicians rather than actually detailing. As a result, the return on investment in the sales function is declining.
According to a new report issued by London-based Datamonitor, sales forces are growing in size, but sales force return on investment is decreasing. The report reveals that physicians have less time to see sales representatives but are contacted by an increasing number as pharmaceutical sales forces expand. Therefore, reps are spending an increasing proportion of their time trying to gain access to physicians rather than actually detailing. As a result, the return on investment in the sales function is declining.
However, according to Datamonitor, rather than increasing the efficiency of their existing sales forces, many companies are seeking to increase their share of voice simply by increasing their sales forces. This fuels further sales force growth by competitors and sets up a cycle of accelerating sales force growth coupled with falling ROI.
Between 1999 and 2001, 64% of the 40 sales forces profiled by Datamonitor increased in size, with an average growth of 21%. In particular, five pharmaceutical companies profiled in the United States increased their sales forces by an average of 42%. Sales force growth is typically attributed to the need to support new product launches and to maintain the company's share of voice in highly competitive markets. The result is even greater competition for the time of increasingly pressured physicians. Seventy-seven percent of companies interviewed by Datamonitor were planning to expand their sales forces further by 2005, so this competition will only increase.
Datamonitor also found that, between 1995 and 2000, the amount of time spent with sales reps by the average U.S. physician decreased from 12 minutes to seven minutes per day. Over the same period, only 20% of physicians increased the number of reps seen daily, despite the significant growth in total sales force head count, implying that each rep is making fewer successful physician visits. Meanwhile, large U.S. practice management companies are increasing the pressure on physicians to reduce the time devoted to activities not directly related to patient care. As a result, sales force ROI is in decline as reps spend more time attempting to gain detailing appointments than making productive visits. According to Datamonitor, if ROI is to improve, companies must identify new ways of meeting the needs of their target audiences and must tailor their detailing programs accordingly. Companies that fail to improve their productivity will experience further ROI decline if sales forces continue to grow at existing rates.
According to the report, many pharmaceutical companies are not structuring their sales forces optimally, following country-specific factors first, instead of their marketed portfolio.
Datamonitor's best practice analysis indicated that companies' marketed portfolios should be the primary influence on sales force structure. While the majority of companies profiled closely match their structure with their marketed portfolios, Datamonitor found that small and medium-sized pharmaceutical companies often do not structure their sales forces in the optimum way.
Datamonitor Analyst Neal Hansen commented: "With country-specific elements superimposed on an optimum global structure, each sales force can meet the specific needs of its target audience both efficiently and effectively." PR
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
Unlocking value and cost savings in patient services with technology and talent
October 2nd 2024Traci Miller, Director, Sonexus™ Access and Patient Support, Cardinal Health, discusses the current digital trends in the patient services industry and how the optimal balance of technology and talent can transform manufacturer-sponsored patient support programs. Hear how Cardinal Health combines best-in-class program and pharmacy operations with smart digital tools to ensure product and patient success and reduce operational costs.